Skip to main content

Table 1 Summary of Case Reports of anti-PD1/PD-L1 induced APS-2 (at least two components)

From: Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

Author (year published) Therapy Age (years) Country Disease Timinga (weeks) Conditions auto-Ab found HLA type Response
Hakami [7] (2019) pembrolizumab 52 Ireland melanoma 21 hypothyroidism
T1DM
  NR NR
Lanzolla [8] (2019) atezolizumab 60 Italy NSCLC 6 T1DM
hypoadrenalism
anti-21-OH DRB1*04
DQB1*03
PD
Sakurai [9] (2018) nivolumab 68 Japan RCC 14 hypothyroidismb
T1DM
anti-TPO
Anti-Tg
DRB1*09:01
DQB1*03:03
NR
Gauci [10] (2017) nivolumab 73 France melanoma 6 hyperthyroidismb
T1DM
anti-GAD
anti-IA2
anti-ZnT8
NR PR
Paepegaey [11] (2017) pembrolizumab 55 France melanoma 12 hypothyroidism
hypoadrenalism
anti-21-OH NR NR
Li [12] (2017) nivolumab 63 USA NSCLC 4 T1DM
hypothyroidism
anti-GAD
anti-TPO
NR PD
Alhusseini [13] (2017) pembrolizumab + ipilimumab 65 USA NSCLC 3 T1DM
hyperthyroidism
anti-GAD
anti-IA
anti-insulin
anti-TPO
NR PR
Lowe [14] (2016) nivolumab + ipilimumab 54 USA melanoma 2 hyperthyroidism
T1DM
anti-GAD DQB1*0602 CR
Kong [15] (2016) pembrolizumab 68 Korea NSCLC 21 T1DM
hyperthyroidism
Nil DRB1*09:01
DQB1*03:03
PR
Hansen [16] (2016) pembrolizumab 58 USA melanoma NR hypothyroidism
T1DM
anti-GAD NR PR
Mellati [17] (2015) NR 66   SCC jaw 7 T1DM
hypothyroidism
anti-TPO
anti-GAD
DR3-DQ2
DR4-DQ8
NR
Hughes [18] (2015) nivolumab + ipilimumab 55 USA melanoma 20 hypothyroidismb
T1DM
  A2.1
DR4
NR
Hughes (2015) pembrolizumab 64 USA melanoma < 4 hypothyroidismb
T1DM
  DR4 NR
  1. Abbreviations: auto-Ab auto-antibody, HLA Human leukocyte antigen, T1DM Type 1 diabetes mellitus, NR Not reported, PD Progressive disease, 21-OH 21-hydroxylase, anti-TPO Anti-thyroid peroxidase, anti-Tg anti-thyroglobulin, anti-GAD anti-glutamic acid decarboxylase, anti-IA2 anti-islet antibody 2, anti-ZnT8 anti-zinc transporter 8, PR partial response, CR complete response
  2. atiming denotes weeks after start of anti-PD1 therapy to onset of APS-2
  3. bauto-immune condition preceded treatment with anti-PD1 axis therapy